Related Experiment Video
Updated: Jun 25, 2026

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease
Published on: July 19, 2024
Characterization of hepatic mitochondrial injury induced by fatty acid oxidation inhibitors
1Drug Safety Evaluation, Allergan, Inc., Irvine, California, USA. vickers_alison@allergan.com
Abstract:
Impairment of liver mitochondrial beta-oxidation is an important mechanism of drug-induced liver injury. Four inhibitors of fatty acid oxidation were compared in short-term rat in vivo studies in which the rats were administered one or four doses. The hepatocellular vacuolation represented ultra-structural mitochondrial changes. Urine nuclear magnetic resonance (NMR) spectroscopy revealed that both FOX988 and SDZ51-641 induced a persistent dicarboxylic aciduria, suggesting an inhibition of mitochondrial beta-oxidation and incomplete fatty acid metabolism. Etomoxir caused minimal mitochondrial ultrastructural changes and induced only transient dicarboxylic aciduria. CPI975 served as a negative control, in that there were no significant perturbations to the mitochondrial ultrastructural morphology or in the urine NMR composition; however, compound exposure was confirmed by the up-regulation of liver gene expression compared to vehicle control. The liver gene expression changes that were altered by the compounds were indicative of mitochondria, general and oxidative stress, and peroxisomal enzymes involved in beta-oxidation, suggestive of a compensatory response to the inhibition in the mitochondria. In addition, both FOX988 and SDZ51-641 up-regulated ribosomal genes associated with apoptosis, as well as p53 pathways linked with apoptosis. In summary, metabonomics and liver gene expression provided mechanistic information on mitochondrial dysfunction and impaired fatty acid oxidation to further define the clinical pathology and histopathology findings of hepatotoxicity.
Insights
Drug-induced liver injury involves impaired mitochondrial beta-oxidation. Metabonomics and gene expression revealed how FOX988 and SDZ51-641 inhibit this process, leading to toxicity.
Area of Science:
- Biochemistry
- Toxicology
- Molecular Biology
Background:
- Drug-induced liver injury (DILI) is often linked to impaired mitochondrial function.
- Mitochondrial beta-oxidation is a key pathway for fatty acid metabolism and energy production in the liver.
Purpose of the Study:
- To investigate the mechanisms of DILI caused by fatty acid oxidation inhibitors.
- To compare the effects of four different inhibitors on mitochondrial function and cellular stress pathways.
Main Methods:
- In vivo studies in rats administered with fatty acid oxidation inhibitors.
- Analysis of hepatocellular ultrastructure, urine nuclear magnetic resonance (NMR) spectroscopy, and liver gene expression.
Main Results:
- FOX988 and SDZ51-641 induced persistent dicarboxylic aciduria, indicating inhibited beta-oxidation and incomplete fatty acid metabolism.
- Etomoxir showed minimal mitochondrial changes and transient dicarboxylic aciduria, while CPI975 served as a negative control.
- Gene expression analysis revealed alterations related to mitochondrial and oxidative stress, peroxisomal beta-oxidation, and apoptosis pathways.
Conclusions:
- Metabonomics and gene expression profiling elucidated the mechanisms of mitochondrial dysfunction and impaired fatty acid oxidation.
- These findings provide mechanistic insights into the clinical and histopathological features of DILI induced by these compounds.
Related Concept Videos
Cellular Injury I: Introduction
Cellular Injury IV: Necrosis
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

